Moreover, the ADA Guidelines 2024 indicate the role of GLP1 agonists and SGLT2 inhibitors in the treatment of atherosclerotic cardiovascular diseases, including peripheral artery disease (PAD) [20]. The gene discussed is SLC5A2; the disease is peripheral arterial disease.